Portal de Periódicos da CAPES

Molecular fingerprints of medulloblastoma and their application to clinical practice

2011; Future Medicine; Volume: 7; Issue: 3 Linguagem: Inglês

10.2217/fon.11.15

1744-8301

Scott L. Pomeroy, Yoon-Jae Cho,

Cancer-related molecular mechanisms research

Future OncologyVol. 7, No. 3 EditorialMolecular fingerprints of medulloblastoma and their application to clinical practiceScott L Pomeroy & Yoon-Jae ChoScott L PomeroyDepartment of Neurology, Children's Hospital Boston & Harvard Medical School, 300 Longwood Ave, CLS 14072, Boston, MA 02115, USA. & Yoon-Jae Cho† Author for correspondenceDepartment of Neurology, Children's Hospital Boston & Harvard Medical School, 300 Longwood Ave, CLS 14072, Boston, MA 02115, USA. Published Online:21 Mar 2011https://doi.org/10.2217/fon.11.15AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: genomicsmedulloblastomamolecular risk-stratificationBibliography1 Cho YJ, Tsherniak A, Tamayo P et al.: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. DOI: 10.1200/JCO.2010.28.5148 (2010) (Epub ahead of print).Google Scholar2 Kool M, Koster J, Bunt J et al.: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS One3(8),E3088 (2008).Crossref, Medline, Google Scholar3 Macdonald TJ, Brown KM, Lafleur B et al.: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet.29(2),143–152 (2001).Crossref, Medline, CAS, Google Scholar4 Northcott PA, Korshunov A, Witt H et al.: Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. DOI: 10.1200/JCO.2009.27.4324 (2010) (Epub ahead of print).Medline, Google Scholar5 Pomeroy SL, Tamayo P, Gaasenbeek M et al.: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature415(6870),436–442 (2002).Crossref, Medline, CAS, Google Scholar6 Thompson MC, Fuller C, Hogg TL et al.: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol.24(12),1924–1931 (2006).Crossref, Medline, CAS, Google Scholar7 Clifford SC, Lusher ME, Lindsey JC et al.: Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle5(22),2666–2670 (2006).Crossref, Medline, CAS, Google Scholar8 Ellison DW, Onilude OE, Lindsey JC et al.: β-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J. Clin. Oncol.23(31),7951–7957 (2005).Crossref, Medline, CAS, Google Scholar9 Fattet S, Haberler C, Legoix P et al.: β-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J. Pathol.218(1),86–94 (2009).Crossref, Medline, CAS, Google Scholar10 Tamayo P, Cho Y-J, Tsherniak A et al.: Predicting relapse in medulloblastoma patients by integrating evidence from clinical and genomic features. J. Clin. Oncol. DOI: 10.1200/JCO.2010.28.1675 (2011) (Epub ahead of print)Google Scholar11 Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL: Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J. Clin. Oncol.22(6),994–998 (2004).Crossref, Medline, CAS, Google Scholar12 Luo B, Cheung HW, Subramanian A et al.: Highly parallel identification of essential genes in cancer cells. Proc. Natl Acad. Sci. USA105(51),20380–20385 (2008).Crossref, Medline, CAS, Google Scholar13 Barbie DA, Tamayo P, Boehm JS et al.: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature462(7269),108–112 (2009).Crossref, Medline, CAS, Google Scholar14 Scholl C, Frohling S, Dunn IF et al.: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell137(5),821–834 (2009).Crossref, Medline, CAS, Google Scholar15 Low JA, De Sauvage FJ: Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol.28(36),5321–5326 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByYB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells4 January 2016 | Oncogene, Vol. 35, No. 32Medulloblastoma development: tumor biology informs treatment decisionsVidya Gopalakrishnan, Rong-Hua Tao, Tara Dobson, William Brugmann & Soumen Khatua13 March 2015 | CNS Oncology, Vol. 4, No. 2 Vol. 7, No. 3 STAY CONNECTED Metrics Downloaded 402 times History Published online 21 March 2011 Published in print March 2011 Information© Future Medicine LtdKeywordsgenomicsmedulloblastomamolecular risk-stratificationFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download